CDSCO panel asks SII for local trial data to approve Covishield as booster

The panel recommended that the firm submit data and proposal for the booster dose approval

Covishield
Photo: Shutterstock
Press Trust of India New Delhi
2 min read Last Updated : Dec 11 2021 | 12:34 AM IST

An expert panel of India's central drug authority which reviewed Serum Institute's application for approval of Covishield as booster dose against COVID-19 on Friday recommended that the firm submit local clinical trial data and proposal along with justification for the booster dose approval, official sources said.

On December 1, Prakash Kumar Singh, director, Government and Regulatory affairs at Serum Institute of India (SII), had sought approval from the Drugs Controller General of India (DCGI) for Covishield as booster dose, citing adequate stock of the vaccine in the country and a demand for a booster shot due to the emergence of new coronavirus variants.

Singh had referred to the UK's Medicines and Healthcare products Regulatory Agency giving a go-ahead to the booster doses of AstraZeneca ChAdOx1 nCoV-19 vaccine in the application.

"The subject expert committee (SEC) on COVID-19 at CDSCO reviewed SII's application and following detailed deliberation recommended that the Pune-based firm should submit local clinical trial data and proposal along with the justification for booster dose approval," a source said.

Singh is learnt to have said in the application that as the world continued to face the pandemic situation, many countries had started administering booster dose of COVID-19 vaccines.

"You are aware that now there is no shortage of Covishield in our country and the demand for a booster dose is increasing day by day from the people who have already taken two doses in view of the ongoing COVID-19 pandemic and emergence of new strains," he had said in the application.

The Union government informed parliament that the National Technical Advisory Group on Immunisation and the National Expert Group on Vaccine Administration for COVID-19 are deliberating and considering scientific evidence for the need and justification for a booster dose against Covid.

According to the information available on www.ourworldindata.org, more than 60 countries across the world are providing booster doses of COVID-19 vaccine, Minister of State for Health Bharati Pravin Pawar said in a written reply on Friday.

Recently, states like Kerala, Rajasthan, Karnataka and Chhattisgarh urged the Centre to decide on allowing booster doses of COVID-19 vaccine amid concerns raised by 'Omicron', the new variant of SARS-CoV-2.

The Delhi High Court had on November 25 directed the Centre to clarify its stand on administering booster doses to those who are fully vaccinated against coronavirus, saying it does not want a second-wave-like situation on account of being conservative.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineCoronavirus Tests

First Published: Dec 10 2021 | 8:38 PM IST

Next Story